Thursday, March 06, 2025

New Defense Stock Coming to Market-VisionWave Technologies Merger with Bannix Acquisition (NASDAQ: $BNIX)

 

New Defense Stock Coming to Market-VisionWave Technologies Merger with Bannix Acquisition (NASDAQ: $BNIX)  

 

Stocks Mentioned: (NASDAQ: $BNIX) (NYSE: $LMT) (NYSE: $GD), (NYSE: $LHX) (NYSE: $NOC)  

 

 

 



 


 

March 6, 2025 -   Investorideas.com, a top 100 investment site for 2025, releases a snapshot on defense stocks as global spending increases, and a new era of security emerges.    

 

According to the International Institute for Strategic Studies, “in 2024, global defense spending reflected intensifying security challenges and reached USD2.46 trillion, up from USD2.24trn the previous year.”

 

As President Trump calls for changes in defense spending, the world is adapting to the new reality that each country needs to build and expand on its own defense budget.

 

Shares of the top defense companies like Lockheed Martin (NYSE:LMT) General Dynamics (NYSE:GD), L3Harris Technologies (NYSE:LHX) and Northrop Grumman Corporation (NYSE:NOC) have stabilized after reaction to proposed defense cuts  and have since seen gains following the recent Trump-Zelenskyy meeting.

 

As defense budgets surge in Germany, France and other countries, some of top European defense stocks saw gains of up to 40% as investors traded on the sentiment of headlines.

 

In US markets, there is a new emerging defense technology company looking to go public.  Bannix Acquisition Corp. (NASDAQ: BNIX) recently filed an amended S-4 registration statement, with details of its target, VisionWave Technologies, Inc., coming into sharper focus. The filing outlines VisionWave’s business model, proprietary technology and commercialization strategy, providing insight into a company poised to revolutionize defense and security through AI-powered autonomous systems, radar technology, and advanced sensing solutions.

 

This news is paid news dissemination for Bannix Acquisition Corp.

 

Read this news, featuring BNIX in full at https://www.investorideas.com/news/2025/defense/03061VisionWave-Technologies.asp

 

VisionWave Technologies is an emerging defense technology company specializing in AI-driven solutions for military, homeland security and industrial applications. The company’s strategy is three-pronged:

 

          1.       Technology Licensing – VisionWave intends to license its proprietary AI and sensor technology to defense contractors and government agencies, enabling integration into existing military and security systems.

          2.       Direct Product Sales – The Company will manufacture and sell unmanned vehicles, remote weapon stations, and advanced radar systems directly to military, law enforcement, and industrial clients.

          3.       Strategic Partnerships – VisionWave is actively pursuing alliances and joint ventures with industry leaders to co-develop customized solutions based on its proprietary technology.

 

The company is transitioning from research and development (R&D) to full commercialization, with several pilot projects already underway.

 

VisionWave’s proprietary technology portfolio is built on AI-driven defense innovations, with key developments including:

 

1. Event-Based AI Vision Technology:

 

Inspired by biological vision systems, this AI-driven sensor technology allows real-time tracking of fast-moving or stealth objects, such as:

   •   Drones

   •   Mortars and rockets

   •   Bullets in mid-air

 

Unlike traditional thermal imaging, VisionWave’s event-based vision sensors process pixel-level changes, functioning like an AI-powered optical radar.

 

2. CoPilot AI: Fully Autonomous Drone Technology:

 

VisionWave’s CoPilot AI enables drones to operate autonomously, including:

   •   Intercepting incoming drones

   •   Executing swarm formations

   •   Adapting to mission requirements in real-time

 

This “fire-and-forget” AI-driven system outperforms human pilots in complex military and security scenarios.

 

3. Vision-RF: AI-Powered Radio Frequency Imaging:

 

One of VisionWave’s most groundbreaking innovations, Vision-RF can convert radio frequency (RF) signals into real-time images, allowing for:

   •   Aerial threat detection

   •   Through-wall visualization

   •   Underground activity monitoring

 

This technology is protected by multiple patents and has significant potential applications in defense, law enforcement, and infrastructure monitoring.

 

4. Remote Weapon Stations (RWS):

 

VisionWave has developed an advanced remote weapon system for combat vehicles and naval applications. This system:

   •   Enhances precision targeting

   •   Provides stabilization for better accuracy

   •   Integrates seamlessly into existing defense platforms

 

The company has already begun production in partnership with a U.S. military contractor, with full-scale manufacturing expected in 2025.

 

5. AI-Enabled Tactical Platforms:

 

VisionWave’s micro-ATV platform is designed for:

   •   Stealthy, high-mobility operations

   •   Law enforcement and Special Forces

   •   Medical evacuation and rapid response

 

This four-wheel-drive electric vehicle offers silent maneuverability, providing an edge over traditional gas-powered military transport.

 

VisionWave is at a critical inflection point, moving from prototype development to commercialization. The company has eight product lines, with several already at Technology Readiness Level (TRL) 7 or higher, meaning they are proven in operational environments.

 

Pilot projects with defense and homeland security agencies are actively being conducted and the company anticipates full-scale commercial production in 2025.

 

VisionWave faces competition from major defense contractors like Lockheed Martin, Northrop Grumman and Raytheon, as well as specialized drone defense firms such as Dedrone and Anduril Industries. However, the company’s proprietary AI-driven approach and patented technologies hopes to provide a strong competitive advantage.

 

Following a successful merger with Bannix Acquisition Corp, VisionWave will become a publicly traded company on NASDAQ under the ticker symbols:  VWAV (common stock) and

VWAVW (warrants).

 

VisionWave Technologies is positioning to be a next-generation defense technology firm with a strong focus on AI-driven military and security solutions. With proprietary radar, vision and autonomous technology, the company plans to disrupt traditional defense markets.

 

Commenting on the current state of the current evolving defense market, CEO of global financial advisory giant deVere Group opines,“ Almost every investor needs exposure to defense stocks amid shifting geopolitical realities.”

 

The comments from Nigel Green come as the Stoxx Europe aerospace and defence index has skyrocketed, as investors reposition for what is now an undeniable reality: defence spending is set to climb for years to come.

 

He says: "With European leaders scrambling to reinforce their military capabilities after the US distanced itself from security commitments, defense companies stand to be major beneficiaries.

 

"We believe that this is likely to be the beginning of a fundamental realignment that will shape markets for the foreseeable future.

 

"The shift is structural. Governments across Europe are coming to terms with the fact that their decades-long reliance on US military backing can no longer be taken for granted.

 

"The Trump administration's refusal to provide clear security guarantees has made it clear that Europe must shoulder more of the burden itself. This will translate into significant, sustained increases in defense budgets.

 

"From Asia to the Middle East, the pattern is clear: countries are prioritizing security and resilience, and the defense sector is the primary beneficiary," notes the deVere Group CEO.

 

According to a recent article quoting US defense analyst Shaun McDougall talking about Trumps’ proposed cuts, “He wants the military to focus solely on its warfighting capabilities, so the administration has begun eliminating efforts like diversity programs that he doesn’t think contribute to that warfighting mentality.”

 

Continued: “Trump’s Republican Party is actively working to increase the defense budget right now. Several key Republican lawmakers who oversee defense committees in Congress argue that the US should be raising its defense budget to at least $1 trillion. It would be hard for Trump to convince them to go the opposite direction and reduce spending by such a large amount.”

 

Behind the knee-jerk market reaction to Trump’s  news, it’s business as usual for the big defense contractors, as on January 31st, the US Navy awarded Lockheed Martin (NYSE: LMT) a $383 million cost-plus-incentive-fee and cost-plus-fixed-fee modification to the existing Lockheed Martin contract for development of the next generation of the Trident II Strategic Weapons System (SWS) D5 missile to continue the nation's sea-based strategic deterrence.

 

For investors following defense stocks- follow the money it will tell the real story. 

 

Research aerospace and defense stocks at Investorideas.com

https://www.investorideas.com/Companies/HomelandDefense/Stock_List.asp

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all.

 

Disclaimer/Disclosure: Disclosure: this news article featuring BNIX/VisionWave is paid for content creation   on Investorideas.com (one thousand eight hundred) .Our site does not make recommendations for purchases or sale of stocks, services or products.  This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This is not investment opinion .All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411

 




Get more 
Defense Stock Investor Ideas - news, articles, and stock directories

 

Friday, February 28, 2025

Exploring Mining Podcast - Market Reset Alert: Gold to Shine, and Potential Mining Sector Boom –Chris Vermeulen Interview

 



 

Exploring Mining Podcast - Market Reset Alert: Gold to Shine, and Potential Mining Sector Boom –Chris Vermeulen Interview

 


February 28, 2025 Investorideas.com, a global investor news source covering mining and metals stocks releases a new episode of the  Exploring Mining Podcast . Host Cali Van Zant talks to Chris Vermeulen, founder & Chief Investment Officer of The Technical Traders Ltd,  about what’s going on with gold, energy, and when we might see miners run again

Learn more at https://thetechnicaltraders.com/

 

Listen to the podcast:

https://www.spreaker.com/episode/market-reset-alert-gold-to-shine-and-potential-mining-sector-boom-chris-vermeulen-interview--64628928

 

Watch on YouTube: https://youtu.be/GzbiOBgNbWI

 

Read this in full at

https://www.investorideas.com/news/2025/exploring-mining/02281Chris-Vermeulen.asp

 

Listen to Exploring Mining on Spotify

Listen to Exploring Mining podcast on iTunes Apple podcasts 

 

Overview:

Chris believes the market is near or at its top, with AI and semiconductor stocks losing momentum and net outflows from major tech stocks. Chris predicts a difficult year ahead with potential bubbles bursting in equities and real estate.

 

He sees an opportunity in gold, silver, and mining stocks after a market reset, similar to the post-2008 crisis rally. Chris suggests that gold might reach $3,050 before potentially pulling back to around $2,400, which he views as a buying opportunity.

 

He recommends considering inverse ETFs, long-term Treasury bond ETFs, and the US Dollar Index as potential investment strategies during market downturns.

 

Chris discusses his belief in a forthcoming rally in the dollar and a potential drop in the energy sector. He notes that energy stocks are trading near all-time highs, while oil prices have been declining, creating a divergence. Chris predicts a significant reset in the energy sector, potentially leading to a 30-50% drop in energy stocks over the next year.

He also mentions the impact this could have on retirees who hold dividend-paying stocks.

 

Chris and Cali discuss the potential for a turnaround in the gold mining sector. Chris suggests that the sector might be nearing a bottom, with a potential 100% return on the index, but cautioned that this could take another year or so. He also notes that gold miners tend to bottom before the stock market does and that late this year or early next year could be the window for the bottom to be put in place.

 

About Chris Vermeulen

Chris Vermeulen is a visionary investor and the pioneering force behind the industry-breaking method known as “Asset Revesting.” In his latest book, “Asset Revesting – How to Exclusively Hold Assets Rising in Value, Profit during Bear Markets, and Continue Building Wealth in Retirement,” Chris unveils this revolutionary approach to investing.

 

Chris’s financial journey began at the young age of 16 in 1997. Harnessing his innate talent for trading and risk management, he earned enough to fund his final year of college, where he obtained a business diploma in operations management. By his 20s, Chris had transitioned into a full-time entrepreneur and trader, achieving financial freedom.

 

A master of technical analysis, Chris developed systematic processes that uncover unique trading and investment opportunities. He is a steadfast advocate for managing portfolio risk and has little faith in the conventional buy-and-hold strategy, which often means clinging to depreciating assets.

 

Chris’s innovative asset allocation strategies emphasize efficiency, resulting in systems that manage portfolio positions with low drawdowns while consistently outperforming the markets. His short-term and long-term strategies provide proven techniques for those seeking to manage and protect their capital.

 

Renowned as an exceptional technical trader with profound market insights, Chris shares his expertise in his book, “Technical Trading Mastery, Second Edition – 7 Steps to Win with Logic,” further cementing his status as a trailblazer in the financial industry.

 

Hear other episodes of the Exploring Mining Podcast , rated as one of the top 30 mining podcasts to listen to in 2025.

 

Website: https://thetechnicaltraders.com/

X: https://x.com/TheTechTraders

YouTube: https://www.youtube.com/c/TheTechnicalTraders

 

The Investorideas.com podcasts are also available on Apple Podcasts, Audible, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google Podcasts and most audio platforms available.

 

Visit the Podcast page at Investorideas.com:

https://www.investorideas.com/Audio/

 

Research mining stocks at Investorideas.com with our free mining stocks directory at Investorideas.com  

 

About Investorideas.com - Big Investing Ideas

Investorideas.com Named as one of 100 Best Investment Blogs and Websites in 2025 (8th)

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure:  Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas @Exploringmining

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be a guest or sponsor this podcast

800-665-0411

 

 


Get more mining stock investor ideas- news, articles, podcasts and stock directories

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


New Biotech Stocks at Investorideas.com; New Biotech Stocks at Investorideas.com; (NYSE American: $CHRO), (OTCQB: $BVAXF; CSE: $BIOV.CN), (NASDAQ: $GRCE), (OTCQB: $MBCOF; TSXV: $MRVL.V), (Nasdaq: $ZVSA), (OTC Pink: $RGBP), (OTCQB: $NRXBF; TSXV: $NRX.V), (NASDAQ: $MTVA)

 New Biotech Stocks at Investorideas.com; New Biotech Stocks at Investorideas.com; (NYSE American: $CHRO), (OTCQB: $BVAXF; CSE: $BIOV.CN), (NASDAQ: $GRCE), (OTCQB: $MBCOF; TSXV: $MRVL.V), (Nasdaq: $ZVSA), (OTC Pink: $RGBP), (OTCQB: $NRXBF; TSXV: $NRX.V), (NASDAQ: $MTVA)

 



 


February 28, 2025 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks added to the biotech stock directory.

 

The newest biotechnology companies are focused on pain alleviation, immunotherapies for infectious disease and cancer treatment, rare and orphan diseases, inflammatory or kidney diseases, Central Nervous System injuries and cardiometabolic diseases.

 

New biotech stocks added include:  Channel Therapeutics Corp. (NYSE American: CHRO), BioVaxys Technology Corp. (OTCQB: BVAXF; CSE: BIOV), Grace Therapeutics, Inc (NASDAQ: GRCE), Marvel Biosciences Corp. (OTCQB: MBCOF; TSXV: MRVL), ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), Regen BioPharma Inc. (OTC Pink: RGBP), NurExone Biologic Inc. (OTCQB: NRXBF) (TSXV: NRX), MetaVia, Inc. (NASDAQ: MTVA).

 

Read this in full at https://www.investorideas.com/news/2025/main/02281Stocks.asp

 

 

Investor Ideas is always researching and searching for new stocks to add to our growing list of free stock directories. The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

New Stocks Added to the Biotech Directories:

Channel Therapeutics Corp. (NYSE American: CHRO) formerly Chromocell Therapeutics Corp. - is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain and post-surgical nerve blocks.

 

BioVaxys Technology Corp. (OTCQB: BVAXFCSE: BIOV) a company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. DPX™ is a patented antigen delivery platform that can incorporate a range of bioactive molecules to produce targeted, long-lasting immune responses enabled by various formulated components. The DPX platform facilitates antigen delivery to regional lymph nodes and has been demonstrated to induce robust and durable T cell and B cell responses in pre-clinical and clinical studies for both cancer and infectious disease.

 

Grace Therapeutics, Inc (NASDAQ: GRCE) (formerly Acasti Pharma Inc.) is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics’ novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutic’s lead clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection with over 40 granted and pending patents. Grace Therapeutics’ lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. In February 2025, Grace Therapeutics announced that its Phase 3 STRIVE-ON safety trial for GTx-104 met its primary endpoint and provided evidence of clinical benefit over orally administered nimodipine.

 

Marvel Biosciences Corp. (OTCQB: MBCOFTSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a "drug redevelopment" approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought, as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies. Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

 

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs. We are well positioned in the rapidly emerging inflammasome space with a highly differentiated monoclonal antibody, Inflammasome ASC Inhibitor IC 100, and in kidney disease with phase 2 Cholesterol Efflux MediatorTM VAR 200. The lead indication for IC 100 is obesity with metabolic complications, and for VAR 200, focal segmental glomerulosclerosis (FSGS). Each therapeutic area offers a “pipeline within a product,” with potential for numerous indications. The total accessible market is over $100 billion.

 

Regen BioPharma Inc. (OTC Pink: RGBP) is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders.

 

NurExone Biologic Inc. (OTCQB: NRXBF) (TSXV: NRX) is a pharmaceutical company that is developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA and European agency, European Medicines Agency. The NurExone platform technology is expected to offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

 

MetaVia, Inc. (NASDAQ: MTVA) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.

 



Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter (X) https://X.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411